Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04961593

PK/PD of Caspofungin in Children Severe Infection

Sponsor: Children's Hospital of Fudan University

View on ClinicalTrials.gov

Summary

Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.

Official title: Pharmacokinetics and Pharmacodynamics of Caspofungin in Children Severe Infection

Key Details

Gender

All

Age Range

3 Months - 18 Years

Study Type

OBSERVATIONAL

Enrollment

60

Start Date

2022-10-01

Completion Date

2026-12-01

Last Updated

2026-02-17

Healthy Volunteers

No

Interventions

DRUG

Caspofungin

For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.

Locations (2)

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China